Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on Signal Switch Receptor Modified Tumor Infiltrating Lymphocytes Injection (GC201 TIL) in Patients With Gynecologic Tumors

NCT05098171 is registered in ClinicalTrials.gov with Shanghai Juncell Therapeutics as lead sponsor.

NCT NCT05098171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05098171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on Signal Switch Receptor Modified Tumor Infiltrating Lymphocytes Injection (GC201 TIL) in Patients With Gynecologic Tumors
Lead sponsor
Shanghai Juncell Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 26, 2021
Completion date
September 25, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gynecologic tumors, effects of immunotherapy, signal switch receptor modified til, treatment side effects